Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Free Paper Session 15: AMD III

08:00 - 09:30 | 07 September | Room: Amphitheatre Havane

Back to Previous

08:00Efficacy of Intravitreal Aflibercept Administered Using a Treat-and-Extend Regimen Over 2 Years in Patients with Neovascular Age-Related Macular Degeneration: The ARIES Study Results
P. Mitchell Australia
08:06Higher-order optical coherence tomography (OCT) fluid burden assessment: analysis from the OSPREY trial
J. Ehlers United States
08:12Correlation between different visual acuity measurements and patient self-reported vision-related quality of life in bilateral neovascular AMD
K. Hatz Switzerland
08:18The impact of compliance on the 12 month outcomes in the treatment of neovascular age related macular degeneration - An experience in a co-payment healthcare system
K. Teo Singapore
08:24Comparison of macular atrophy in eyes with neovascular age related macular degeneration treated with VEGF inhibitors using a treat-and-extend or a pro re nata regimen: four year results of the manex study
K. Spooner Australia
08:30The effectiveness of intravitreal aflibercept in routine clinical practice in patients with treatment-naïve neovascular age-related macular degeneration (nAMD): GALAXY – an integrated pooled analysis of two studies from different healthcare systems
L. Kodjikian France
08:36Fluorescence lifetime imaging ophthalmoscopy (FLIO) in AMD
L. Sauer United States
08:42A cluster of 48 cases of symptomatic silicone droplets following intravitreal anti-VEGF injections addressed by switching to silicone-free syringes
M. Sivertsen Norway
08:48Macular atrophy in Anti-VEGF Treated Neo-vascular AMD: incidence and risk factors
M. Cachulo Portugal
08:54Low health literacy levels in patients with chronic retinal disease
M. Krogh Nielsen Denmark
09:00Key efficacy outcomes and treatment intervals with treat-and-extend (T&E) ranibizumab compared to aflibercept for neovascular age-related macular degeneration (nAMD): The 24-month, randomized, RIVAL study
M. Gillies Australia
09:06Central retinal thickness measurements in exudative age-related macular degeneration refractory to anti-vegf: influence of time parameters
M. Zola Switzerland
09:12Intravitreal aflibercept treat-and-extend dosing for wet age-related macular degeneration: Week 16 fluid status and 96-week results from the ALTAIR study
M. Ohji Japan
09:18Extended q16w dosing potential for faricimab in neovascular age-related macular degeneration: STAIRWAY phase 2 trial
F. Holz Germany
Back to Previous

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved